Reversed phase HPLC analysis of mobocertinib and its impurities and studies on the structure and biological activity of a new degradation product

The developed RP-HPLC method is suitable for the simultaneous detection of mobocertinib and its impurities, providing significant advantages for process development and quality control. Imp-A, a novel compound, demonstrated promising anticancer activity in vitro. However, further in vivo studies are required to fully assess its therapeutic potential, which may hold promise for clinical applications in cancer treatment.